Status:
COMPLETED
Oligomeric Alpha-synuclein in Multiple System Atrophy
Lead Sponsor:
University Hospital, Bordeaux
Conditions:
Multiple System Atrophy (MSA)
Eligibility:
All Genders
30+ years
Brief Summary
The main objectives are to determine on one hand whether oligomeric alpha-synuclein levels are increased in MSA patients compared to controls and on other hand whether there is a good agreement betwee...
Detailed Description
Multiple system atrophy (MSA) is a rare neurodegenerative disorder which is characterized by a variable combination of parkinsonism, cerebellar dysfunction, autonomic failure, and additional signs. N...
Eligibility Criteria
Inclusion
- MSA patients
- o Inclusion criteria: Patients suffering from "probable" MSA according to clinical consensus criteria (Gilman et al, 2008), Age \>30 Written informed consent Patient covered by the national health system
- o exclusion criteria: UMSARS IV score \> 4 points Patient under tutelage Patient unable to give consent Patients receiving anticoagulants, showing abnormal coagulation on blood testing or thrombocytopenia are excluded from this study
- Controls (patients requiring spinal tap without suffering from a neurodegenerative disorder) o Inclusion criteria: Patients not suffering from a neurodegenerative disorder and requiring a spinal tap Age \>30 Written informed consent Patient covered by the national health system o exclusion criteria: Similar to MSA patients
Exclusion
Key Trial Info
Start Date :
November 26 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 21 2018
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT01485549
Start Date
November 26 2012
End Date
November 21 2018
Last Update
June 27 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bordeaux University Hospital
Pessac, France, 33604